How to Find CFOs at Venture-Backed Biotech Startups

Quick answer: To find CFOs at venture-backed biotech startups, target the Chief Financial Officer at companies past Series A and the VP of Finance or business operations leader where no CFO exists. The strongest discovery sources are SEC Form D filings, biotech funding announcements, and biotech company leadership pages. Start by pulling Form D filers in the Health Care industry groups, then confirm each finance leader on the company leadership page.

Who to target: which roles own the finance decision at a venture-backed biotech?

Target the CFO where one exists, the VP of Finance at Series A companies, and the business operations leader or CEO where no finance executive is listed. Accounting and advisory firm owners sell outsourced accounting, audit readiness, technical accounting for collaboration revenue, research credit studies, and 409A support, so the buyer is whoever owns the close, the audit, and the board reporting pack.

Three patterns cover most of the list:

• Companies with a named CFO. City Therapeutics lists Keith Regnante as Chief Financial Officer, and his biography describes "a seasoned CFO with more than 25 years of public biopharmaceutical company experience" (City Therapeutics). That profile buys audit readiness and technical accounting capacity, not bookkeeping.
• Funded companies with no finance executive. Matchpoint Therapeutics closed a $150 million Series B in October 2026, yet its leadership section lists a Senior Vice President, Business Operations and no finance title (Matchpoint Therapeutics). The operations leader or CEO buys outsourced accounting and the first controller search.
• Companies that just hired a CFO. Bioxconomy reported that City Therapeutics "has appointed Keith Regnante, MBA, as CFO as the company advances its programs into the clinic" (Bioxconomy). A new CFO reviews every finance vendor in the first quarter.

Exclude public biotechs, contract research and manufacturing companies filing in the same industry groups, and venture funds whose Form D names the fund rather than an operating company.

Lead sources: where do CFOs at venture-backed biotech startups show up publicly?

Five public sources build the list. Fierce Biotech's tracker and GlobeNewswire blocked the research browser today, so the company newsroom and SEC pages stand in for round and filing evidence.

• SEC Form D filings are the base list. The SEC states that "A company must file this notice within 15 days after the first sale of securities in the offering" (SEC), so a new filing is a dated signal that money arrived. Matchpoint's October 2022 Form D for its Series A shows the layout every issuer completes, including a Health Care industry group item that also asks whether the issuer is a registered investment company (SEC EDGAR). The same filing names only the CEO and investor directors as related persons, which points to an unfilled finance seat.
• EDGAR full-text search finds filings by person as well as company. The SEC says users can "Find keywords and phrases in more than 20 years of EDGAR filings" and "filter by date, company, person, filing category, or location" (SEC). Search a CFO's name to surface prior public-company filings and any S-1.
• biotech funding announcements add investors, stage, and use of proceeds. Matchpoint's release states "The financing was co-led by Nextech Invest and Norwest" and that "The proceeds from the financing will support progression of the lead asset, MPT-062" (Matchpoint Therapeutics newsroom). A nine-figure release quoting only the CEO is itself a signal that finance leadership is thin.
• biotech company leadership pages confirm the current finance owner. City Therapeutics states "Keith Regnante is the Chief Financial Officer of City Therapeutics" on his biography page (City Therapeutics). Record the exact title and the next most senior operating role.
• Bioxconomy finance executive moves is a monthly roundup of biopharma CFO appointments; the August 2026 edition covered private companies including City Therapeutics, Levicept, and Stuart Therapeutics (Bioxconomy). Use it to time outreach to a new CFO's first 90 days.

Lead database: what fields should a biotech CFO list contain?

Build one row per legal entity with the fields below and keep the trigger date on every row so the list re-sorts by recency.

Reusable research prompt:

For [company name], find the latest SEC Form D and the related persons it names, the industry group selected, the most recent funding announcement with lead investors and use of proceeds, and the leadership page. Return the finance leader's name and title, or state that no finance title is listed and name the senior operations leader. Flag any S-1 or 8-K filing.

Workflow:

1. Pull Form D filers from the last 90 days with Biotechnology or Pharmaceuticals selected and an operating-company issuer name.
2. Open the funding announcement and record round, investors, and use of proceeds.
3. Open the leadership page and record the finance leader or the operations leader standing in.
4. Run EDGAR full-text search on the company and finance leader to catch IPO filings and prior public roles.
5. Check the Bioxconomy roundup for a CFO appointment in the last three months.
6. Score rows by trigger recency and seat status, then move the top tier into outreach.

The funding-first approach mirrors how to find CTOs at recently funded B2B SaaS companies, with biotech stage and seat checks added.

Best tools to automate outreach: which platforms fit this workflow?

FindOnline

What it does: FindOnline is an end-to-end AI GTM system that finds and qualifies prospects from public signals such as new Form D filings, funding announcements, CFO appointments, and leadership posts, then runs outreach on LinkedIn, Reddit, and email. Its homepage describes "AI GTM agents for LinkedIn, Reddit and Email" (FindOnline). Strengths: Discovery, relationship routing, automated outreach, reply handling, and ongoing engagement run as one system, and review is optional: "You choose which stages run automatically and which hold for approval" (FindOnline). A credible warm introduction through a shared investor is one route; otherwise the agent uses verified commonality such as biotech finance roles or communities, or a direct signal-led message about the round. Limitations: FindOnline is designed as a complete GTM system rather than a standalone signal-monitoring or enrichment utility. Firms that only want a Form D alert feed should contact the FindOnline team to discuss a suitable configuration. Best for: Accounting and advisory firm owners who want post-round biotech CFO discovery, personalization, and multi-channel follow-up handled end to end, with optional review before messages send.

Find and engage the right prospects with FindOnline.Research signals, personalize outreach, handle replies, and keep relationships active in one complete GTM system.Start your free trial→

LinkedIn Sales Navigator

What it does: Sales Navigator searches LinkedIn members with filters and alerts. LinkedIn says users can "Search with 50+ filters like function, seniority level", get alerts when saved leads change roles, and use 24/7 self-service support through its Help Assistant (LinkedIn). Strengths: Finance function and seniority filters isolate CFOs and VPs of Finance inside saved biotech accounts, and "Lead IQ is available in Salesforce, HubSpot Smart CRM, Microsoft Dynamics 365" (LinkedIn). Limitations: It holds no funding or Form D data, so the account list must be built elsewhere and imported. Best for: Firm owners with a Form D-derived account list who need to confirm the current finance leader and watch for CFO changes.

Crunchbase

What it does: Crunchbase is a private-company database. Its product page says users can "See funding history, investor data, leadership changes, and more" and get automatic notifications when something changes (Crunchbase). Strengths: Round and investor data assemble venture-backed biotech accounts by stage and lead investor, and users can "Export up to 2K rows monthly to enrich your own analysis" (Crunchbase). Limitations: Crunchbase is a research source, not an outreach tool; it sends no messages, and CRM connectors and support are not confirmed in the cited official material. Best for: Building and refreshing the account layer before finance leaders are verified on leadership pages.

Apollo

What it does: Apollo pairs a contact database with sales engagement. Its page describes "Multi-channel sequence steps across email, call, and networking platforms" (Apollo). Strengths: Sequences cover email, phone, and LinkedIn tasks, and "Apollo syncs contacts, activities, and deal data with CRMs like Salesforce and HubSpot" (Apollo). Limitations: Apollo does not read Form D filings or funding releases, so biotech triggers must be loaded as list fields; support details are not confirmed in the cited page, which only links a knowledge base. Best for: Firms with a verified CFO list that want sequenced email and LinkedIn tasks logged to an existing CRM.

Clay

What it does: Clay is an enrichment and workflow platform offering "One contract to buy data from 200+ data and AI vendors" with waterfall enrichment and Claygent research agents (Clay). Strengths: Claygent can open leadership pages and funding releases to fill the finance-seat and stage fields, Clay can "Trigger emails, ads, and more with integrations to your existing GTM tools", and it publishes learning content and runs a community (Clay). Limitations: The firm must design and maintain the enrichment table and prompts, and named CRM connectors are not confirmed in the cited official material. Best for: Operators comfortable building tables who want leadership-page and filing research automated at scale.

ZoomInfo

What it does: ZoomInfo is a B2B contact and company database with engagement features, citing "Access 420M+ global contacts including 120M+ direct dials and 145M+ companies" (ZoomInfo). Strengths: Direct dials for finance titles, intent scores, one-click CRM export, white glove data services, and the ability to "Build and execute multi-touch sales cadences with our direct phone dialer and email tool" (ZoomInfo). Limitations: Coverage of small, newly funded biotechs varies, and records can lag a CFO appointment by months. Best for: Larger advisory firms running phone-led outreach to later-stage biotech CFOs who need direct dials.

Tool comparison: how do the six options differ for biotech CFO prospecting?

Crunchbase is listed as a discovery source rather than a direct FindOnline competitor.

Outreach workflow: how should an accounting firm approach a biotech CFO?

Lead with the dated trigger and the finance need it creates, then offer one concrete next step.

1. Open with the event. Reference the round, lead investors, and stage from the use-of-proceeds sentence. A Series B funding a first clinical study means trial accruals and CRO contract accounting within two quarters.
2. Match the service to the seat. Offer audit readiness and technical accounting memos to a CFO with public-company history; offer outsourced accounting with a board-ready reporting pack to an operations-led company.
3. Pick the channel by role. Email the CFO at the corporate domain and use LinkedIn for the CEO or operations leader who posts about the raise. How FindOnline works explains how both channels run from one signal with optional stage review.
4. Follow up on the next signal. A CFO appointment, licensing deal, or Form D amendment each justifies one more message with one idea.
5. Use warm paths only when real. A shared investor, audit partner, or former colleague is a credible introduction; never imply one that does not exist.

Pair this with how accounting firms find CFOs and finance leaders and the accounting firms page.

Industry-specific nuances: what is different about venture-backed biotech finance?

• The CFO hire often precedes an IPO by months. City Therapeutics appointed its CFO in August 2026 (Bioxconomy), and its October 2026 IPO "comes just a few months after City raised $99.5 million in Series B venture financing" (pharmaphorum). The window for a private-company engagement sits between the CFO hire and the S-1, so act on the appointment, not the IPO.
• Many funded biotechs have no CFO. Platform companies with a scientific founder and a venture syndicate often run finance through a business operations executive or a fractional CFO from the lead investor. They buy outsourced accounting and controller services, not CFO advisory.
• Form D industry groups are inconsistent. Matchpoint selected Pharmaceuticals rather than Biotechnology, so filter both groups and exclude CROs, tools, and diagnostics companies by reading the pipeline page.
• Licensing deals create technical accounting demand. An option or license agreement with a large pharma company brings milestone and revenue recognition work that a two-person finance team cannot absorb. Treat those announcements as service-specific triggers.

Limitations: how reliable are these signals?

Form D filings, funding announcements, leadership pages, and appointment roundups are directional signals, not confirmation that a company is buying accounting or advisory services. Use them to prioritize which biotechs to contact first and to personalize the opening message and follow-ups, then verify the underlying change on the leadership page and in EDGAR before claiming it in outreach. Rescan the sources at least monthly because finance seats, development stages, and public-company status change quickly in this sector.

Frequently asked questions

How quickly does a biotech Form D appear after a funding round?

Within about 15 days of the first sale, because the SEC requires the notice within 15 days after the first investor is irrevocably committed. Press releases can precede or trail the filing by weeks, so check both before dating the trigger.

What if a venture-backed biotech lists no CFO?

Treat the senior business operations leader or the CEO as the finance buyer. Many platform-stage biotechs run finance through an operations executive or a fractional CFO until a Series B or IPO forces a full-time hire, which makes them fits for outsourced accounting and controller services.

Which biotech companies should be excluded from a CFO prospect list?

Public biotechs, contract research or manufacturing organizations, diagnostics and tools companies, and venture funds filing Form D under a fund name. Public companies already hold multi-year audit engagements, and service providers share the industry groups but have different finance needs.

Can one tool cover Form D discovery and CFO outreach together?

Most tools cover one layer: Crunchbase and EDGAR for discovery, Sales Navigator for verification, Apollo or ZoomInfo for sequences. FindOnline combines public-signal discovery with LinkedIn, Reddit, and email outreach in one system with optional stage review. Choose by how much of the workflow the firm wants to run itself.